Current guidelines recommend alectinib (second-generation), brigatinib (second-generation), or lorlatinib (third-generation) ALK TKIs as the preferred first-line (1L) treatment for ALK-positive advanced or metastatic NSCLC [3-5]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.